Commerce Department Launches Section 232 Investigation into Pharmaceutical Imports’ Impact on National Security

The Commerce Department has initiated a Section 232 investigation to assess the potential impact of pharmaceutical and pharmaceutical ingredient imports on U.S. national security. The investigation will focus on whether the volume of these imports, and the sources from which they originate, pose a threat. The Commerce Department launched this investigation under Section 232 of the Trade Expansion Act of 1962. The inquiry will delve into the degree to which reliance on foreign pharmaceuticals and active pharmaceutical ingredients could weaken the nation’s defense industrial base or create vulnerabilities in critical supply chains. This examination will involve gathering data and analysis on import volumes, countries of origin, and the domestic capacity to produce these essential goods. The findings of the investigation could potentially lead to recommendations for policy changes or actions aimed at mitigating any identified risks to national security.

Newsflash | Powered by GeneOnline AI
Date: April 14, 2025

Related posts:

Research: Drug Pricing Models Key to Pharma Success; Value Demonstration is Crucial Beyond Patent Expiration Generic Pharma Mergers Surge Amid Evolving Market Report: Strategic Patent Extensions Could Add Billions to Pharmaceutical Revenue Rocatinlimab Highlighted in GlobalData Analysis as Potential New Approach for Moderate-to-Severe Atopic Dermatitis Treatment

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後